Literature DB >> 18312289

High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack.

Juan Macías1, Rosa B Palacios, Evangelina Claro, Julio Vargas, Salvador Vergara, José A Mira, Nicolás Merchante, Juan E Corzo, Juan A Pineda.   

Abstract

BACKGROUND: Most of the prevalent cases of hepatitis C virus (HCV) infection are attributable to intravenous drug using. However, a substantial number of individuals, particularly noninjecting drug users (NIDU), report no identifiable source of HCV exposure. This may be interpreted as inaccurate reporting of past intravenous exposure or as the presence of an unidentified source of HCV infection. Because of this, we evaluated the prevalence of and factors associated with HCV infection among NIDU.
METHODS: One hundred and eighty-two individuals who were attended from 2003 to 2004 in a drug addiction facility because of noninjecting drug use were included.
RESULTS: HCV infection was detected in 23 (12.6%) participants. Sharing the inhalation tube of crack cocaine [adjusted odds ratio (AOR) 3.6, 95% confidence interval (CI) 1.3-9.8, P=0.01], presence of tattoos (AOR 3.5, 95% CI 1.3-9.1, P=0.02) and age >or=34 years (AOR 3.9, 95% CI 1.3-11.6, P=0.01) 3.9 were independently associated with HCV infection.
CONCLUSION: The prevalence of HCV infection in NIDU is higher than in general population. HCV infection is more likely among older drug users, those with tattoos and crack cocaine users that share the inhalation implements.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18312289     DOI: 10.1111/j.1478-3231.2008.01688.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  28 in total

1.  The beginning of a new era in understanding hepatitis C virus prevention.

Authors:  Josiah D Rich; Lynn E Taylor
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

2.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

3.  A 38-year-old man who uses crack cocaine.

Authors:  Amy H W Sur; Lawrence C Loh
Journal:  CMAJ       Date:  2015-09-28       Impact factor: 8.262

4.  Crack pipe sharing among street-involved youth in a Canadian setting.

Authors:  Tessa Cheng; Evan Wood; Paul Nguyen; Julio Montaner; Thomas Kerr; Kora DeBeck
Journal:  Drug Alcohol Rev       Date:  2014-07-25

5.  High prevalence of abscesses and self-treatment among injection drug users in Tijuana, Mexico.

Authors:  Robin A Pollini; Manuel Gallardo; Samreen Hasan; Joshua Minuto; Remedios Lozada; Alicia Vera; María Luisa Zúñiga; Steffanie A Strathdee
Journal:  Int J Infect Dis       Date:  2010-04-08       Impact factor: 3.623

Review 6.  KASL clinical practice guidelines: management of hepatitis C.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

7.  Non-cardiogenic pulmonary edema, rhabdomyolysis and myocardial injury following heroin inhalation: a case report.

Authors:  G Bazoukis; A Spiliopoulou; K Mourouzis; P Grigoropoulou; A Yalouris
Journal:  Hippokratia       Date:  2016 Jan-Mar       Impact factor: 0.471

8.  Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center.

Authors:  Shikha Garg; Lynn E Taylor; Chris Grasso; Kenneth H Mayer
Journal:  Clin Infect Dis       Date:  2013-02-05       Impact factor: 9.079

9.  A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Douglas Y Shapiro; Sandra D Comer
Journal:  Addiction       Date:  2013-03-13       Impact factor: 6.526

Review 10.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.